

[Skip to main content](#)

Clofibrate (Atromid-S)

??? ??????: 30 ?????2/????? 2017

The most common is nausea. Less frequently encountered gastrointestinal reactions are vomiting, loose stools, dyspepsia, flatulence, and abdominal distress. Reactions reported less often than gastrointestinal ones are headache, dizziness, and fatigue; muscle cramping, aching, and weakness; skin rash, urticaria, and pruritus; dry brittle hair, and alopecia.

The following reported adverse reactions are listed alphabetically by systems:

Cardiovascular

Increased or decreased angina.

Cardiac arrhythmias.

Both swelling and phlebitis at site of xanthomas.

Dermatologic

Allergic reactions including urticaria.

Skin rash.

Pruritus.

Dry skin and dry, brittle hair.

Alopecia.

Toxic epidermal necrolysis.

Erythema multiforme.

Stevens-Johnson syndrome.

Gastrointestinal

Gallstones.

Nausea.

Vomiting.

Diarrhea.

Gastrointestinal upset (bloating, flatulence, abdominal distress).

Hepatomegaly (not associated with hepatotoxicity).

Stomatitis and gastritis.

Genitourinary

Findings consistent with renal dysfunction as evidenced by dysuria, hematuria, proteinuria, decreased urine output. One patient's renal biopsy suggested "allergic reaction."

Impotence and decreased libido.

Hematologic

Leukopenia.

Potential of anticoagulant effect.

Anemia.

Eosinophilia.

Agranulocytosis.

Musculoskeletal

Myalgia (muscle cramping, aching, weakness).

"Flu-like" symptoms.

Myositis.

Myopathy.

Rhabdomyolysis in the setting of preexisting renal insufficiency.

Arthralgia.

Neurologic

Fatigue, weakness, drowsiness.

Dizziness.

Headache.

Miscellaneous

Weight gain.

Polyphagia.

Laboratory Findings

Abnormal liver-function tests as evidenced by increased transaminase (SGOT and SGPT), BSP retention, and increased thymol turbidity.

Proteinuria.

Increased creatine phosphokinase.

Hyperkalemia in association with renal insufficiency and continuous ambulatory peritoneal dialysis treatment.

Reported adverse reactions whose direct relationship with the drug has not been established: peptic ulcer, gastrointestinal hemorrhage, rheumatoid arthritis, tremors, increased perspiration, systemic lupus erythematosus, blurred vision, gynecomastia, thrombocytopenic purpura.